1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Medtronic/Tandem Patent Agreement Paves Way For Diabetes Product Development

 
• By Marion Webb

Tandem Diabetes Care and Medtronic have signed a patent cross-license agreement that paves the way for joint development of future diabetes products and services while avoiding potential legal disagreements.

Handshake of businessmen

Tandem Diabetes Care, Inc. and Medtronic plc have entered into a non-exclusive patent agreement that applies to existing and new products, enabling the two companies to work together on future diabetes pump technology. Tandem was first on the market to receive US Food and Drug Administration clearance for its integrated infusion pump called t:slim X2 while Medtronic is trailing behind in this device category.

This announcement comes just weeks after Tandem finalized an agreement with Abbott Diabetes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

 
• By Marion Webb

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By Shubham Singh

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

Abbott Embeds Libre Glucose Data In Epic EHR, Expanding Digital Health Footprint

 
• By Shubham Singh

Through this partnership, data stored in LibreView – Abbott’s cloud-based diabetes data management system – can automatically flow into Epic, allowing clinicians using Epic to view a patient’s CGM data before, during and after visits without toggling between systems or requesting manual uploads.

Analysts See Insulet’s Appointment Of Ashley McEvoy As CEO As A Positive Move

 
• By Marion Webb

Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.

More from Device Area

FDA And Boston Scientific Face Legal Action Over Spinal Device Safety

 
• By Elizabeth Orr

A patient, Dena Lawler, is suing Boston Scientific and the US FDA over alleged harm from a spinal stimulator device. Lawler claims inadequate regulatory review allowed dangerous modifications to the device, which then caused her pain and other health issues. She is calling for reconsideration of the device approvals.

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Harbinger Health Targets High-Mortality Cancers First With AI-Driven MCED Platform

 
• By Shubham Singh

With a projected FDA submission within the next two to three years, Harbinger is prioritizing cancers based on lethality, prevalence, and unmet diagnostic need. Pancreatic and biliary cancers – often diagnosed at late stages and lacking established screening programs – will be among the initial targets.